Journal article

Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease

Emily K Wright, Michael A Kamm, Peter De Cruz, Amy L Hamilton, Fabiyola Selvaraj, Fred Princen, Alexandra Gorelik, Danny Liew, Lani Prideaux, Ian C Lawrance, Jane M Andrews, Peter A Bampton, Simon L Jakobovits, Timothy H Florin, Peter R Gibson, Henry Debinski, Finlay A Macrae, Douglas Samuel, Ian Kronborg, Graham Radford-Smith Show all

JOURNAL OF CROHNS & COLITIS | OXFORD UNIV PRESS | Published : 2018

Abstract

Background: Anti-TNF prevents postoperative Crohn's disease recurrence in most patients but not all. This study aimed to define the relationship between adalimumab pharmacokinetics, maintenance of remission and recurrence. Methods: As part of a study of postoperative Crohn's disease management, some patients undergoing resection received prophylactic postoperative adalimumab. In these patients, serum and fecal adalimumab concentration and serum anti-adalimumab antibodies [AAAs] were measured at 6, 12 and 18 months postoperatively. Levels of Crohn's disease activity index [CDAI], C-reactive protein [CRP] and fecal calprotectin [FC] were assessed at 6 and 18 months postoperatively. Body mass i..

View full abstract